Rep. Josh Gottheimer Sells Insmed, Inc. (NASDAQ:INSM) Stock

Representative Josh Gottheimer (Democratic-New Jersey) recently sold shares of Insmed, Inc. (NASDAQ:INSM). In a filing disclosed on July 07th, the Representative disclosed that they had sold between $1,001 and $15,000 in Insmed stock on June 10th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Nintendo (OTCMKTS:NTDOY) on 6/17/2026.
• Sold $1,001 – $15,000 in shares of Agree Realty (NYSE:ADC) on 6/1/2026.
• Sold $1,001 – $15,000 in shares of Novozymes A/S (OTCMKTS:NVZMY) on 6/1/2026.
• Sold $1,001 – $15,000 in shares of Nestle (OTCMKTS:NSRGY) on 6/1/2026.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 6/1/2026.
• Sold $1,001 – $15,000 in shares of Booking (NASDAQ:BKNG) on 6/1/2026.
• Sold $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 5/27/2026.
• Purchased $1,001 – $15,000 in shares of Lumentum (NASDAQ:LITE) on 5/22/2026.
• Sold $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 5/22/2026.
• Purchased $1,001 – $15,000 in shares of Micron Technology (NASDAQ:MU) on 5/21/2026.

Insmed Stock Up 3.3%

Shares of Insmed stock opened at $116.53 on Thursday. The business has a fifty day simple moving average of $107.94 and a 200 day simple moving average of $138.83. The stock has a market cap of $25.26 billion, a PE ratio of -20.27 and a beta of 0.78. The company has a quick ratio of 4.10, a current ratio of 4.47 and a debt-to-equity ratio of 0.80. Insmed, Inc. has a 12 month low of $90.39 and a 12 month high of $212.75.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.14. The firm had revenue of $305.96 million for the quarter, compared to analysts’ expectations of $300.81 million. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The company’s revenue was up 229.7% compared to the same quarter last year. During the same quarter last year, the business earned ($1.42) earnings per share. Research analysts predict that Insmed, Inc. will post -2.55 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. FNY Investment Advisers LLC bought a new stake in Insmed during the second quarter worth about $138,000. PensionDanmark Pensionsforsikringsaktieselskab increased its stake in shares of Insmed by 8.0% in the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 31,393 shares of the biopharmaceutical company’s stock valued at $3,347,000 after buying an additional 2,338 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of Insmed by 245.0% during the second quarter. Assenagon Asset Management S.A. now owns 218,270 shares of the biopharmaceutical company’s stock worth $23,272,000 after purchasing an additional 155,011 shares during the period. Avior Wealth Management LLC lifted its holdings in Insmed by 23.0% during the 2nd quarter. Avior Wealth Management LLC now owns 4,913 shares of the biopharmaceutical company’s stock worth $524,000 after buying an additional 919 shares during the period. Finally, Harbor Investment Advisory LLC bought a new stake in Insmed in the second quarter valued at approximately $52,000.

Wall Street Analyst Weigh In

INSM has been the topic of several analyst reports. Truist Financial cut their target price on shares of Insmed from $205.00 to $185.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. JPMorgan Chase & Co. reduced their target price on Insmed from $180.00 to $179.00 and set an “overweight” rating on the stock in a report on Monday, June 8th. Jefferies Financial Group started coverage on Insmed in a research note on Monday, March 16th. They issued a “buy” rating and a $228.00 target price for the company. Wells Fargo & Company lowered their price target on Insmed from $177.00 to $160.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Insmed in a research report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $211.86.

Insider Activity

In related news, CEO William Lewis sold 21,398 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $103.32, for a total value of $2,210,841.36. Following the transaction, the chief executive officer owned 258,917 shares in the company, valued at $26,751,304.44. The trade was a 7.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Michael Alexander Smith sold 6,149 shares of the stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $108.47, for a total value of $666,982.03. Following the sale, the insider owned 41,613 shares of the company’s stock, valued at approximately $4,513,762.11. The trade was a 12.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 54,590 shares of company stock worth $6,078,011 in the last 90 days. 2.10% of the stock is owned by company insiders.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.

Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.

Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.

Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.